Takeda Trial for Crohn's Perianal Fistulas Treatment Misses Primary Endpoint
Takeda said Tuesday its trial of darvadstrocel in the treatment of complex Crohn's Perianal Fistulas didn't meet its primary endpoint based on topline data.
Stay updated with breaking news from Jp 4502. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Takeda said Tuesday its trial of darvadstrocel in the treatment of complex Crohn's Perianal Fistulas didn't meet its primary endpoint based on topline data.
American depositary receipts of Takeda Pharmaceutical Co. rose more than 1% in the extended session Tuesday after the Japan-based company said its dengue...
By Denny Jacob Takeda Pharmaceutical's vaccine to prevent dengue, qdenga, was recommended by a World Health Organization advisory group. The company, which...
By Denny Jacob Takeda Pharmaceutical plans to voluntarily withdraw exkivity following discussions with the Food and Drug Administration. The company, which...
By Kosaku Narioka Takeda Pharmaceutical said Thursday that its first-quarter net profit fell 15% from a year earlier despite revenue growth in several key...